Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 6.0 CNY, compared to the current stock price of 5.54 CNY [4]. Core Views - The company's revenue and performance are under pressure, with a year-on-year revenue decline of 6.21% to 248.56 billion CNY in Q1 2025, and a net profit decrease of 19.46% to 6.03 billion CNY [1][2]. - Despite the overall revenue decline, the real estate development segment saw significant growth, with a year-on-year increase of 59.48% [1]. - The company has a robust backlog of contracts, with a total of 7.23 trillion CNY in uncompleted contracts as of March 2025, which is a 5.1% increase from the previous year [3]. Revenue and Performance Summary - In Q1 2025, the revenue breakdown by segment is as follows: Infrastructure 216.80 billion CNY (down 7.99%), Design Consulting 4.67 billion CNY (down 2.21%), Equipment Manufacturing 6.25 billion CNY (down 5.77%), Real Estate Development 6.67 billion CNY (up 59.48%), and Other Businesses 14.90 billion CNY (up 3.15%) [1]. - The company's gross profit margin decreased to 8.46%, with specific margins for segments: Infrastructure 7.13%, Design Consulting 22.48%, Equipment Manufacturing 19.27%, and Real Estate Development 13.10% [2]. - The operating cash flow showed a net outflow of 77.40 billion CNY, which is an increase in outflow by 9.33 billion CNY year-on-year [2]. Contract and Order Summary - The new contract signing in Q1 2025 totaled 560.10 billion CNY, a decrease of 9.9% year-on-year, with domestic contracts at 494.43 billion CNY (down 13.6%) and international contracts at 65.67 billion CNY (up 33.4%) [3]. - The breakdown of new contracts by business area includes Engineering Construction 421.43 billion CNY (down 10.4%), Equipment Manufacturing 11.77 billion CNY (down 18.7%), Specialty Real Estate 6.92 billion CNY (up 2.8%), Asset Management 26.96 billion CNY (up 123.7%), Resource Utilization 6.45 billion CNY (down 16.7%), and Emerging Businesses 72.14 billion CNY [3].

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 28.97 CNY per share [6]. Core Views - The company reported a slight decline in revenue for 2024, with total revenue of 1.823 billion CNY, down 2.07% year-on-year, and a significant net loss of 497 million CNY, a decrease of 307.39% year-on-year [1][11]. - The first quarter of 2025 showed a revenue of 266 million CNY, down 5.32% year-on-year, but a net profit of -30 million CNY, an increase of 11.65% year-on-year [1]. - The company is expected to improve its profitability significantly as production capacity utilization rates increase to optimal levels [2]. Summary by Sections Financial Performance - In 2024, the overall gross margin was 42.12%, a decrease of 11.87 percentage points year-on-year, with net profit margin at -27.27%, down 40.15 percentage points year-on-year [2]. - The company anticipates revenue growth in the coming years, projecting revenues of 2.187 billion CNY in 2025, 2.537 billion CNY in 2026, and 2.841 billion CNY in 2027 [11]. Business Segments - The company has established a strong position in the electric vehicle testing market, becoming the largest designated supplier for a major U.S. electric vehicle manufacturer, with increasing orders [3]. - The consumer electronics testing segment is currently under pressure due to industry cycles, but is expected to recover as market conditions improve and the company continues to innovate [4]. Strategic Outlook - The company is focusing on dual-track development in the semiconductor testing equipment sector, emphasizing customized solutions for global benchmark clients and accelerating the import substitution process [10]. - The second-generation SoC testing machine has reached international standards, and the company has successfully developed the first domestic Sub-6G RF testing system [10].

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 49.45 CNY for the next six months [5][9]. Core Insights - The company's core business has rebounded, leading to significant growth in Q1 2025, with revenue reaching 606 million CNY and net profit attributable to shareholders at 62 million CNY, representing year-on-year increases of 20.05% and 272.28% respectively [2][4]. - The growth is primarily driven by the high-margin front-end life science reagent business, which has seen a notable increase in revenue share compared to the same period last year [2][3]. - Continuous improvements in operational efficiency and strict cost control have also contributed to the enhancement of the company's performance [2][3]. Summary by Sections Business Performance - In Q1 2025, the company achieved revenue of 606 million CNY and a net profit of 62 million CNY, with year-on-year growth rates of 20.05% and 272.28% respectively [2][4]. - The front-end life science reagent business has shown strong growth, significantly increasing its revenue share [2][3]. Competitive Advantage - The company has established a differentiated competitive advantage in the front-end life science reagent business through product innovation, which is a core driver of its growth [3]. - As of the end of 2024, the company has a product pipeline of over 47,000 tool compounds and biochemical reagents, and approximately 92,000 molecular building blocks [3]. Backend Operations - The backend operations, focusing on specialty generic APIs and related intermediates, are progressing steadily, with ongoing industrial base construction in various locations [4]. - The company has enhanced its service capabilities in the ADC field, with over 110 ADC projects undertaken and 12 small molecule products related to ADC drugs having completed FDA sec-DMF filings [4]. Financial Projections - The company is projected to achieve revenues of 2.688 billion CNY, 3.139 billion CNY, and 3.612 billion CNY for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 18.41%, 16.76%, and 15.09% [9][13]. - The net profit attributable to shareholders is expected to be 243 million CNY, 284 million CNY, and 339 million CNY for the same years, with growth rates of 20.7%, 16.5%, and 19.7% [9][13].

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 6.49 CNY over the next six months [4][7]. Core Views - The company reported a revenue of 555.34 billion CNY in Q1 2025, representing a year-on-year growth of 1.1%, and a net profit attributable to shareholders of 15.01 billion CNY, which is a 0.6% increase year-on-year [2][3]. - The growth in revenue is attributed to enhanced project management, the implementation of key projects, and proactive customer resource expansion [2]. - The company is focusing on strategic emerging industries, achieving a revenue of 45.3 billion CNY in Q1 2025, which is a significant year-on-year increase of 34.2% [2]. - The company signed new contracts worth 1,270.2 billion CNY in Q1 2025, marking a 6.9% increase year-on-year, with a notable 40% increase in new contracts for infrastructure projects [4]. Summary by Sections Revenue and Performance - In Q1 2025, the company achieved a revenue of 555.34 billion CNY, with various segments showing different growth rates: construction revenue at 364.9 billion CNY (down 0.2%), infrastructure at 128.3 billion CNY (up 0.5%), real estate development at 53.7 billion CNY (up 15.5%), and surveying and design at 2.3 billion CNY (down 11.3%) [2]. - The company’s net profit for Q1 2025 was 15.01 billion CNY, with a slight decline in gross margin to 7.85% [3]. Cost and Cash Flow Management - The gross margin faced pressure, decreasing by 0.24 percentage points year-on-year, while the company effectively controlled its expense ratio at 3.65% [3]. - The operating cash flow showed improvement, with a net outflow of 95.85 billion CNY, which is a reduction of 0.743 billion CNY compared to the previous year [3]. Contract and Order Growth - The company’s new contract signing in Q1 2025 reached 1,270.2 billion CNY, with a 6.9% year-on-year increase, driven by a 40% increase in infrastructure contracts [4]. - The structure of the construction business is continuously optimizing, with significant growth in contracts for affordable housing and educational facilities [4]. Financial Projections - The company is projected to achieve revenues of 2,285.57 billion CNY, 2,381.56 billion CNY, and 2,472.06 billion CNY for the years 2025, 2026, and 2027, respectively, with corresponding net profits of 48.54 billion CNY, 50.88 billion CNY, and 53.01 billion CNY [7][8].

Investment Rating - The investment rating for the company is maintained at Buy-A, with a 6-month target price of 159.85 CNY [5]. Core Insights - The company reported Q1 2025 revenue of 0.81 billion CNY, a year-over-year decrease of 1.9%, while the net profit attributable to shareholders reached 0.06 billion CNY, reflecting a significant year-over-year increase of 337.5% [2][3]. - The domestic market is expected to improve due to the gradual recovery of consumer spending and the introduction of new products, while the overseas market is anticipated to contribute additional revenue through products featuring Google TV [2][3]. - The company's gross profit margin increased by 6.0 percentage points year-over-year, driven by a reduction in the cost of upstream DMD chips and ongoing supply chain improvements [2][3]. Financial Performance Summary - Q1 2025 revenue decreased by 1.9% year-over-year, while the net profit margin increased by 6.0 percentage points [2][3]. - The company’s gross margin improved by 6.0 percentage points year-over-year, with a gross profit increase of 8.7% [2][3]. - The forecasted EPS for 2025, 2026, and 2027 is 4.70 CNY, 5.20 CNY, and 5.77 CNY respectively, indicating a positive growth trajectory [3][4]. Financial Projections - The projected revenue for 2025 is 3.76 billion CNY, with a net profit of 0.33 billion CNY, reflecting a net profit margin of 8.7% [4][11]. - The company is expected to achieve a PE ratio of 27.3 in 2025, decreasing to 22.2 by 2027 [4][11]. - The net profit is projected to grow significantly, with a year-over-year increase of 173.9% in 2025 [11]. Market Position - The company is positioned as a leader in the domestic projection industry, having completed a comprehensive product lineup including LED, laser, LCD, and ultra-short throw projectors [3]. - The company’s market strategy includes leveraging the domestic replacement policy to boost sales and expanding its international presence with new product offerings [2][3].

分区域看，2024 年内销实现收入 23.94 亿元，同比增加 0.96%；外销 实现收入 4.51 亿元，同比增长 46.69%，主要原因系泰国豪悦营业收 入大幅提升所致。 事件：豪悦护理发布 2024 年报。24A 公司实现营业收入 29.29 亿元， 同比增长 6.25%；归母净利润 3.88 亿元，同比下降 11.65%；扣非后 归母净利润 3.76 亿元，同比下降 11.10%。24Q4 公司实现营业收入 8.88 亿元，同比增长 30.19%；归母净利润 0.93 亿元，同比下降 27.55%；扣非后归母净利润 0.88 亿元，同比下降 33.55%。 婴儿卫生用品销量增长，外销收入大幅提升 分品类看，2024 年公司婴儿卫生用品、成人卫生用品、其他产品分别 实现收入 20.60/5.52/2.32 亿元，同比增长 4.3%/-0.5%/57.6%。从 量价拆分来看，24 年婴儿卫生用品、成人卫生用品的销量分别为 30.44、7.35 亿片，分别同比增长 12.3%、8.4%，公司根据客户需求 以销定产模式进行生产，因业务增加使婴儿卫生用品生产量和销售量 增长；单片均价分别为 0.68、0.75 ...

2025 年 04 月 30 日 骄成超声(688392.SH) 业绩拐点持续兑现，平台化发展穿越周 期 公司动态分析 证券研究报告 | | 其他专用机械 | | --- | --- | | 投资评级 | 买入-A | | | 首次评级 | | 6 个月目标价 | 55.65 元 | | 股价 (2025-04-29) | 49.55 元 | | 交易数据 | | | 总市值(百万元) | 5,688.34 | | 流通市值(百万元) | 3,459.52 | | 总股本(百万股) | 114.80 | | 流通股本(百万股) | 69.82 | | 12 个月价格区间 | 27.94/61.0 元 | 事件： 骄成超声发布 2025 年一季报，2025Q1 实现营收 1.48 亿元，同比 +22.35%，实现归母净利润 0.24 亿元，同比+2152.47%。 核心观点： 公司深耕超声波设备，在过去下游锂电资本开支放缓的背景下，公司 依托自身超声波平台化技术，大力开拓汽车线束、半导体领域等业务， 2024 年业绩环比逐季改善，2025Q1 实现收入增速 22.35%，利润同比 大幅改善。展望未来，短期看锂电 ...

Investment Rating - The report assigns a "Buy-A" investment rating to the company with a target price of 48.65 CNY for the next six months [6][18]. Core Views - The company experienced a temporary decline in performance in Q1 2025, with revenue and net profit decreasing by 5.79% and 29.61% year-on-year, respectively, due to intensified industry competition and a drop in average order prices [2][5]. - Despite the temporary setback, the company has shown a strong growth trend in new orders, with a net increase in contract value exceeding 2 billion CNY in Q1 2025, representing a 20% year-on-year growth [3][4]. - The company's global operational capabilities are improving, with a significant increase in overseas projects, reaching 233 clinical research projects by the end of 2024, a 20% increase year-on-year [4]. Financial Forecast and Valuation Analysis - The company is projected to achieve net profits of 12.02 billion CNY, 13.28 billion CNY, and 14.98 billion CNY for the years 2025 to 2027, reflecting year-on-year growth rates of 196.6%, 10.5%, and 12.8%, respectively [5][12]. - The expected earnings per share (EPS) for 2025 is 1.39 CNY, with a price-to-earnings (PE) ratio of 35 times, leading to the target price of 48.65 CNY [5][18]. - Revenue forecasts for 2025, 2026, and 2027 are 71.43 billion CNY, 78.70 billion CNY, and 88.28 billion CNY, with corresponding year-on-year growth rates of 8.17%, 10.18%, and 12.17% [12][20].

2025 年 04 月 30 日 小熊电器(002959.SZ) Q1 收入延续良好增长趋势 事件：小熊电器公布公布 2025 年一季度报告。公司 2025Q1 实 现收入 13.2 亿元，YoY+10.6%；实现归母净利润 1.3 亿元，YoY- 14.0%。展望后续，随着公司不断拓展新品类，持续发力海外市场， 收入有望保持增长趋势。 Q1 收入增长趋势良好：国内家电以旧换新政策拉动厨房小家电 行业需求。根据久谦，Q1 小熊线上销售额 YoY+22%。从品类来看， Q1 小熊线上咖啡机、豆浆机、破壁机等品类销售额实现快速增长。 展望后续，以旧换新有望带动公司内销业务保持良好增长趋势。 另一方面，公司持续提升海外产品研发和策划能力，积极拓展海 外渠道。海外业务有望持续贡献增长动力。此外，2024 年 7 月公 司并表罗曼智能，为公司收入带来增量。 Q1 盈利能力同比下降：Q1 公司毛销差同比+0.9pct，我们认为 主要因为以旧换新带动产品均价提升。Q1 公司归母净利率同比- 2.8pct。Q1 公司净利率下降的主要原因包括：1）公司研发和管理 费用支出有所增加。Q1 研发/管理费用率分别同比+0.7 pct ...

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 17.28 CNY, compared to the current stock price of 15.63 CNY as of April 29, 2025 [5]. Core Views - The company reported a significant decline in revenue and net profit for 2024, with revenue at 3.377 billion CNY, down 40.76% year-on-year, and net profit at 492 million CNY, down 56.03% year-on-year. The first quarter of 2025 also showed a decline in revenue to 663 million CNY, down 56.30% year-on-year, and net profit at 57 million CNY, down 77.62% year-on-year [1][2]. - The company is undergoing a strategic transformation as part of its "Six Five Plan," focusing on optimizing its business model, channels, and strategies to enhance long-term competitiveness. There are signs of improvement in Q1 2025 performance compared to the previous quarter [1][2]. - The company is committed to its unique research and development path, focusing on pediatric, adult digestive, and gynecological treatments, with nearly 40 drug candidates in development as of the end of 2024 [3]. Financial Performance Summary - In 2024, the company's gross margin was 44.89%, down 11.40 percentage points year-on-year, while the net margin was 14.89%, down 5.55 percentage points year-on-year. The decline in net margin was less severe than that of gross margin due to effective cost control [2]. - For Q1 2025, the gross margin improved to 37.29%, up 45.49 percentage points quarter-on-quarter, and the net margin improved to 8.87%, up 33.93 percentage points quarter-on-quarter [2]. - The company expects revenue growth rates of 4.6%, 15.2%, and 19.0% for 2025, 2026, and 2027, respectively, with net profit growth rates of 2.5%, 31.6%, and 34.1% for the same years [8].